146 patents
Page 6 of 8
Utility
Methods of Treating Cancer
19 Aug 20
The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
Sarah K. KNUTSON, Natalie WARHOLIC, Heike KEILHACK
Filed: 21 Jan 20
Utility
Amine-substituted Heterocyclic Compounds As EHMT2 Inhibitors, Salts Thereof, and Methods of Synthesis Thereof
5 Aug 20
The present disclosure relates to amine-substituted heterocyclic compounds.
John Emmerson CAMPBELL, Kenneth William DUNCAN, James Edward John MILLS, Michael John MUNCHHOF
Filed: 17 Oct 18
Utility
Hydrochloride salt form for EZH2 inhibition
13 Jul 20
Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
Kevin Wayne Kuntz, Hyeong Wook Choi, Steven Mathieu, Kristen Sanders, Arani Chanda
Filed: 4 Jun 18
Utility
Isoxazole carboxamides as irreversible SMYD inhibitors
1 Jun 20
Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
Filed: 10 Jan 19
Utility
Use of EZH2 Inhibitors for Treating Cancer
27 May 20
The disclosure provides methods of treating, identifying and/or selecting for treatment a subject having a cancer in which an immune checkpoint protein is upregulated.
Scott DAIGLE, Kat COSMOPOULOS
Filed: 31 May 18
Utility
Method for Treating Cancer
20 May 20
The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
Heike KEILHACK, Sarah K. KNUTSON
Filed: 21 Oct 19
Utility
Aryl-or Heteroaryl-substituted Benzene Compounds
20 May 20
The present invention relates to aryl- or heteroaryl-substituted benzene compounds.
Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
Filed: 21 Oct 19
Utility
PRMT5 inhibitors and uses thereof
18 May 20
Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash
Filed: 3 Aug 15
Utility
Isoxazole Carboxamide Compounds
13 May 20
Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
Filed: 29 Sep 19
Utility
Method of Treating Malignant Rhabdoid Tumor of the Ovary (Mrto)/small Cell Cancer of the Ovary of the Hypercalcemic Type(sccoht) with an EZH2 Inhibitor
6 May 20
The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor.
Heike KEILHACK
Filed: 3 Oct 19
Utility
Arginine methyltransferase inhibitors and uses thereof
27 Apr 20
Richard Chesworth, Lorna Helen Mitchell, Gideon Shapiro
Filed: 25 Jan 18
Utility
CARM1 inhibitors and uses thereof
27 Apr 20
Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
Filed: 1 Oct 18
Utility
Substituted Cyclohexylamine Compounds
22 Apr 20
Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof
Filed: 18 Oct 18
Utility
Methods of Using EHMT2 Inhibitors
15 Apr 20
The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof.
John Emmerson CAMPBELL, Kenneth William DUNCAN, Elayne PENEBRE, Kat COSMOPOULOS, Christine KLAUS
Filed: 29 Mar 18
Utility
Combination Therapy for Treating Cancer
15 Apr 20
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Heike KEILHACK, Sarah K. KNUTSON, Kevin W. KUNTZ
Filed: 16 Sep 19
Utility
DOT1L Inhibitors for Use In the Treatment of Leukemia
15 Apr 20
The present invention relates to DOT1L inhibitors.
Roy M. Pollock, Scott R. Daigle
Filed: 18 Sep 19
Utility
Substituted Pyrrolidine Compounds
1 Apr 20
Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
Filed: 4 Aug 19
Utility
Combination Therapy for Treating Cancer
1 Apr 20
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Heike KEILHACK, Roberto PILI
Filed: 5 Sep 19
Utility
Combination Therapy for Treating Cancer
11 Mar 20
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount.
Maria Alejandra RAIMONDI
Filed: 30 Nov 17
Utility
Inhibition of SMARCA2 for Treatment of Cancer
4 Mar 20
The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer.
Alexandra Rose GRASSIAN, Allison DREW
Filed: 27 Feb 18